Global and Japan Hemophilia A Drug Market Insights, Forecast to 2026

Publisher Name :
Date: 28-Oct-2020
No. of pages: 148
Inquire Before Buying

Hemophilia A Drug market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia A Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Hemophilia A Drug market is segmented into

- ATXF-8117

- BAY-1093884

- BIVV-001

- BS-027125

- Concizumab

- CSL-689

- Others

Segment by Application, the Hemophilia A Drug market is segmented into

- Clinic

- Hospital

- ASCs

Regional and Country-level Analysis

The Hemophilia A Drug market is analysed and market size information is provided by regions (countries).

The key regions covered in the Hemophilia A Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Hemophilia A Drug Market Share Analysis

Hemophilia A Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hemophilia A Drug business, the date to enter into the Hemophilia A Drug market, Hemophilia A Drug product introduction, recent developments, etc.

The major vendors covered:

- Bayer AG

- BioMarin Pharmaceutical Inc

- Bioverativ Inc

- Catalyst Biosciences Inc

- Chugai Pharmaceutical Co Ltd

- CSL Ltd

- DBV Technologies SA

- Dimension Therapeutics Inc

- EpiVax Inc

- Expression Therapeutics LLC

- Green Cross Corp

- Idogen AB

- Immusoft Corp

- LFB SA

- mAbxience SA

Global and Japan Hemophilia A Drug Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Hemophilia A Drug Product Introduction
1.2 Market Segments
1.3 Key Hemophilia A Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hemophilia A Drug Market Size Growth Rate by Type
1.4.2 ATXF-8117
1.4.3 BAY-1093884
1.4.4 BIVV-001
1.4.5 BS-027125
1.4.6 Concizumab
1.4.7 CSL-689
1.4.8 Others
1.5 Market by Application
1.5.1 Global Hemophilia A Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 ASCs
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hemophilia A Drug Market Size, Estimates and Forecasts
2.1.1 Global Hemophilia A Drug Revenue 2015-2026
2.1.2 Global Hemophilia A Drug Sales 2015-2026
2.2 Global Hemophilia A Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Hemophilia A Drug Historical Market Size by Region (2015-2020)
2.3.1 Global Hemophilia A Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Hemophilia A Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Hemophilia A Drug Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Hemophilia A Drug Sales Forecast by Region (2021-2026)
2.4.2 Global Hemophilia A Drug Revenue Forecast by Region (2021-2026)
3 Global Hemophilia A Drug Competitor Landscape by Players
3.1 Global Top Hemophilia A Drug Sales by Manufacturers
3.1.1 Global Hemophilia A Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Hemophilia A Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Global Hemophilia A Drug Manufacturers by Revenue
3.2.1 Global Hemophilia A Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Hemophilia A Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hemophilia A Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hemophilia A Drug Revenue in 2019
3.2.5 Global Hemophilia A Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Hemophilia A Drug Price by Manufacturers
3.4 Global Hemophilia A Drug Manufacturing Base Distribution, Product Types
3.4.1 Hemophilia A Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hemophilia A Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hemophilia A Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hemophilia A Drug Market Size by Type (2015-2020)
4.1.1 Global Hemophilia A Drug Sales by Type (2015-2020)
4.1.2 Global Hemophilia A Drug Revenue by Type (2015-2020)
4.1.3 Hemophilia A Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hemophilia A Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hemophilia A Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hemophilia A Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hemophilia A Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hemophilia A Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hemophilia A Drug Market Size by Application (2015-2020)
5.1.1 Global Hemophilia A Drug Sales by Application (2015-2020)
5.1.2 Global Hemophilia A Drug Revenue by Application (2015-2020)
5.1.3 Hemophilia A Drug Price by Application (2015-2020)
5.2 Hemophilia A Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hemophilia A Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hemophilia A Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hemophilia A Drug Price Forecast by Application (2021-2026)
6 Japan by Players, Type and Application
6.1 Japan Hemophilia A Drug Market Size YoY Growth 2015-2026
6.1.1 Japan Hemophilia A Drug Sales YoY Growth 2015-2026
6.1.2 Japan Hemophilia A Drug Revenue YoY Growth 2015-2026
6.1.3 Japan Hemophilia A Drug Market Share in Global Market 2015-2026
6.2 Japan Hemophilia A Drug Market Size by Players (International and Local Players)
6.2.1 Japan Top Hemophilia A Drug Players by Sales (2015-2020)
6.2.2 Japan Top Hemophilia A Drug Players by Revenue (2015-2020)
6.3 Japan Hemophilia A Drug Historic Market Review by Type (2015-2020)
6.3.1 Japan Hemophilia A Drug Sales Market Share by Type (2015-2020)
6.3.2 Japan Hemophilia A Drug Revenue Market Share by Type (2015-2020)
6.3.3 Japan Hemophilia A Drug Price by Type (2015-2020)
6.4 Japan Hemophilia A Drug Market Estimates and Forecasts by Type (2021-2026)
6.4.1 Japan Hemophilia A Drug Sales Forecast by Type (2021-2026)
6.4.2 Japan Hemophilia A Drug Revenue Forecast by Type (2021-2026)
6.4.3 Japan Hemophilia A Drug Price Forecast by Type (2021-2026)
6.5 Japan Hemophilia A Drug Historic Market Review by Application (2015-2020)
6.5.1 Japan Hemophilia A Drug Sales Market Share by Application (2015-2020)
6.5.2 Japan Hemophilia A Drug Revenue Market Share by Application (2015-2020)
6.5.3 Japan Hemophilia A Drug Price by Application (2015-2020)
6.6 Japan Hemophilia A Drug Market Estimates and Forecasts by Application (2021-2026)
6.6.1 Japan Hemophilia A Drug Sales Forecast by Application (2021-2026)
6.6.2 Japan Hemophilia A Drug Revenue Forecast by Application (2021-2026)
6.6.3 Japan Hemophilia A Drug Price Forecast by Application (2021-2026)
7 North America
7.1 North America Hemophilia A Drug Market Size YoY Growth 2015-2026
7.2 North America Hemophilia A Drug Market Facts & Figures by Country
7.2.1 North America Hemophilia A Drug Sales by Country (2015-2020)
7.2.2 North America Hemophilia A Drug Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Hemophilia A Drug Market Size YoY Growth 2015-2026
8.2 Europe Hemophilia A Drug Market Facts & Figures by Country
8.2.1 Europe Hemophilia A Drug Sales by Country
8.2.2 Europe Hemophilia A Drug Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Hemophilia A Drug Market Size YoY Growth 2015-2026
9.2 Asia Pacific Hemophilia A Drug Market Facts & Figures by Country
9.2.1 Asia Pacific Hemophilia A Drug Sales by Region (2015-2020)
9.2.2 Asia Pacific Hemophilia A Drug Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Hemophilia A Drug Market Size YoY Growth 2015-2026
10.2 Latin America Hemophilia A Drug Market Facts & Figures by Country
10.2.1 Latin America Hemophilia A Drug Sales by Country
10.2.2 Latin America Hemophilia A Drug Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Hemophilia A Drug Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Hemophilia A Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Hemophilia A Drug Sales by Country
11.2.2 Middle East and Africa Hemophilia A Drug Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Bayer AG
12.1.1 Bayer AG Corporation Information
12.1.2 Bayer AG Description and Business Overview
12.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bayer AG Hemophilia A Drug Products Offered
12.1.5 Bayer AG Recent Development
12.2 BioMarin Pharmaceutical Inc
12.2.1 BioMarin Pharmaceutical Inc Corporation Information
12.2.2 BioMarin Pharmaceutical Inc Description and Business Overview
12.2.3 BioMarin Pharmaceutical Inc Sales, Revenue and Gross Margin (2015-2020)
12.2.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Products Offered
12.2.5 BioMarin Pharmaceutical Inc Recent Development
12.3 Bioverativ Inc
12.3.1 Bioverativ Inc Corporation Information
12.3.2 Bioverativ Inc Description and Business Overview
12.3.3 Bioverativ Inc Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Bioverativ Inc Hemophilia A Drug Products Offered
12.3.5 Bioverativ Inc Recent Development
12.4 Catalyst Biosciences Inc
12.4.1 Catalyst Biosciences Inc Corporation Information
12.4.2 Catalyst Biosciences Inc Description and Business Overview
12.4.3 Catalyst Biosciences Inc Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Catalyst Biosciences Inc Hemophilia A Drug Products Offered
12.4.5 Catalyst Biosciences Inc Recent Development
12.5 Chugai Pharmaceutical Co Ltd
12.5.1 Chugai Pharmaceutical Co Ltd Corporation Information
12.5.2 Chugai Pharmaceutical Co Ltd Description and Business Overview
12.5.3 Chugai Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Products Offered
12.5.5 Chugai Pharmaceutical Co Ltd Recent Development
12.6 CSL Ltd
12.6.1 CSL Ltd Corporation Information
12.6.2 CSL Ltd Description and Business Overview
12.6.3 CSL Ltd Sales, Revenue and Gross Margin (2015-2020)
12.6.4 CSL Ltd Hemophilia A Drug Products Offered
12.6.5 CSL Ltd Recent Development
12.7 DBV Technologies SA
12.7.1 DBV Technologies SA Corporation Information
12.7.2 DBV Technologies SA Description and Business Overview
12.7.3 DBV Technologies SA Sales, Revenue and Gross Margin (2015-2020)
12.7.4 DBV Technologies SA Hemophilia A Drug Products Offered
12.7.5 DBV Technologies SA Recent Development
12.8 Dimension Therapeutics Inc
12.8.1 Dimension Therapeutics Inc Corporation Information
12.8.2 Dimension Therapeutics Inc Description and Business Overview
12.8.3 Dimension Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Dimension Therapeutics Inc Hemophilia A Drug Products Offered
12.8.5 Dimension Therapeutics Inc Recent Development
12.9 EpiVax Inc
12.9.1 EpiVax Inc Corporation Information
12.9.2 EpiVax Inc Description and Business Overview
12.9.3 EpiVax Inc Sales, Revenue and Gross Margin (2015-2020)
12.9.4 EpiVax Inc Hemophilia A Drug Products Offered
12.9.5 EpiVax Inc Recent Development
12.10 Expression Therapeutics LLC
12.10.1 Expression Therapeutics LLC Corporation Information
12.10.2 Expression Therapeutics LLC Description and Business Overview
12.10.3 Expression Therapeutics LLC Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Expression Therapeutics LLC Hemophilia A Drug Products Offered
12.10.5 Expression Therapeutics LLC Recent Development
12.11 Bayer AG
12.11.1 Bayer AG Corporation Information
12.11.2 Bayer AG Description and Business Overview
12.11.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Bayer AG Hemophilia A Drug Products Offered
12.11.5 Bayer AG Recent Development
12.12 Idogen AB
12.12.1 Idogen AB Corporation Information
12.12.2 Idogen AB Description and Business Overview
12.12.3 Idogen AB Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Idogen AB Products Offered
12.12.5 Idogen AB Recent Development
12.13 Immusoft Corp
12.13.1 Immusoft Corp Corporation Information
12.13.2 Immusoft Corp Description and Business Overview
12.13.3 Immusoft Corp Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Immusoft Corp Products Offered
12.13.5 Immusoft Corp Recent Development
12.14 LFB SA
12.14.1 LFB SA Corporation Information
12.14.2 LFB SA Description and Business Overview
12.14.3 LFB SA Sales, Revenue and Gross Margin (2015-2020)
12.14.4 LFB SA Products Offered
12.14.5 LFB SA Recent Development
12.15 mAbxience SA
12.15.1 mAbxience SA Corporation Information
12.15.2 mAbxience SA Description and Business Overview
12.15.3 mAbxience SA Sales, Revenue and Gross Margin (2015-2020)
12.15.4 mAbxience SA Products Offered
12.15.5 mAbxience SA Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Hemophilia A Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hemophilia A Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Hemophilia A Drug Market Segments
Table 2. Ranking of Global Top Hemophilia A Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hemophilia A Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of ATXF-8117
Table 5. Major Manufacturers of BAY-1093884
Table 6. Major Manufacturers of BIVV-001
Table 7. Major Manufacturers of BS-027125
Table 8. Major Manufacturers of Concizumab
Table 9. Major Manufacturers of CSL-689
Table 10. Major Manufacturers of Others
Table 11. Global Hemophilia A Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 12. Global Hemophilia A Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 13. Global Hemophilia A Drug Sales by Regions 2015-2020 (K Pcs)
Table 14. Global Hemophilia A Drug Sales Market Share by Regions (2015-2020)
Table 15. Global Hemophilia A Drug Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Hemophilia A Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 17. Global Hemophilia A Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Hemophilia A Drug Sales Share by Manufacturers (2015-2020)
Table 19. Global Hemophilia A Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Hemophilia A Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia A Drug as of 2019)
Table 21. Hemophilia A Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Hemophilia A Drug Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Hemophilia A Drug Price (2015-2020) (USD/Pcs)
Table 24. Hemophilia A Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Hemophilia A Drug Product Type
Table 26. Date of International Manufacturers Enter into Hemophilia A Drug Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Hemophilia A Drug Sales by Type (2015-2020) (K Pcs)
Table 29. Global Hemophilia A Drug Sales Share by Type (2015-2020)
Table 30. Global Hemophilia A Drug Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Hemophilia A Drug Revenue Share by Type (2015-2020)
Table 32. Hemophilia A Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Hemophilia A Drug Sales Share by Type (2021-2026)
Table 34. Global Hemophilia A Drug Sales by Application (2015-2020) (K Pcs)
Table 35. Global Hemophilia A Drug Sales Share by Application (2015-2020)
Table 36. Global Hemophilia A Drug Sales Share by Application (2021-2026)
Table 37. Global Hemophilia A Drug Sales Market Share Forecast by Application (2021-2026)
Table 38. Global Hemophilia A Drug Revenue by Application (2015-2020) (US$ Million)
Table 39. Global Hemophilia A Drug Revenue Market Share Forecast by Application (2021-2026)
Table 40. Japan Hemophilia A Drug Sales (K Pcs) of Key Companies (2015-2020)
Table 41. Japan Hemophilia A Drug Sales Share by Company (2015-2020)
Table 42. Japan Hemophilia A Drug Revenue (US$ Million) by Company (2015-2020)
Table 43. Japan Hemophilia A Drug Sales (K Pcs) by Type (2015-2020)
Table 44. Japan Hemophilia A Drug Sales Share by Type (2015-2020)
Table 45. Japan Hemophilia A Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 46. Japan Hemophilia A Drug Price (K Pcs) by Type (2015-2020)
Table 47. Japan Hemophilia A Drug Sales (K Pcs) by Type (2021-2026)
Table 48. Japan Hemophilia A Drug Sales Share by Type (2021-2026)
Table 49. Japan Hemophilia A Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 50. Japan Hemophilia A Drug Revenue Share by Type (2021-2026)
Table 51. Japan Hemophilia A Drug Price (K Pcs) by Type (2021-2026)
Table 52. Japan Hemophilia A Drug Sales (K Pcs) by Application (2015-2020)
Table 53. Japan Hemophilia A Drug Sales Share by Application (2015-2020)
Table 54. Japan Hemophilia A Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 55. Japan Hemophilia A Drug Sales (K Pcs) by Application (2021-2026)
Table 56. Japan Hemophilia A Drug Sales Share by Application (2021-2026)
Table 57. Japan Hemophilia A Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 58. Japan Hemophilia A Drug Revenue Share by Application (2021-2026)
Table 59. North America Hemophilia A Drug Sales by Country (2015-2020) (K Pcs)
Table 60. North America Hemophilia A Drug Sales Market Share by Country (2015-2020)
Table 61. North America Hemophilia A Drug Revenue by Country (2015-2020) (US$ Million)
Table 62. North America Hemophilia A Drug Revenue Market Share by Country (2015-2020)
Table 63. Europe Hemophilia A Drug Sales by Country (2015-2020) (K Pcs)
Table 64. Europe Hemophilia A Drug Sales Market Share by Country (2015-2020)
Table 65. Europe Hemophilia A Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Europe Hemophilia A Drug Revenue Market Share by Country (2015-2020)
Table 67. Asia Pacific Hemophilia A Drug Sales by Region (2015-2020) (K Pcs)
Table 68. Asia Pacific Hemophilia A Drug Sales Market Share by Region (2015-2020)
Table 69. Asia Pacific Hemophilia A Drug Revenue by Region (2015-2020) (US$ Million)
Table 70. Asia Pacific Hemophilia A Drug Revenue Market Share by Region (2015-2020)
Table 71. Latin America Hemophilia A Drug Sales by Country (2015-2020) (K Pcs)
Table 72. Latin America Hemophilia A Drug Sales Market Share by Country (2015-2020)
Table 73. Latin Americaa Hemophilia A Drug Revenue by Country (2015-2020) (US$ Million)
Table 74. Latin America Hemophilia A Drug Revenue Market Share by Country (2015-2020)
Table 75. Middle East and Africa Hemophilia A Drug Sales by Country (2015-2020) (K Pcs)
Table 76. Middle East and Africa Hemophilia A Drug Sales Market Share by Country (2015-2020)
Table 77. Middle East and Africa Hemophilia A Drug Revenue by Country (2015-2020) (US$ Million)
Table 78. Middle East and Africa Hemophilia A Drug Revenue Market Share by Country (2015-2020)
Table 79. Bayer AG Corporation Information
Table 80. Bayer AG Description and Business Overview
Table 81. Bayer AG Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 82. Bayer AG Hemophilia A Drug Product
Table 83. Bayer AG Recent Development
Table 84. BioMarin Pharmaceutical Inc Corporation Information
Table 85. BioMarin Pharmaceutical Inc Description and Business Overview
Table 86. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 87. BioMarin Pharmaceutical Inc Product
Table 88. BioMarin Pharmaceutical Inc Recent Development
Table 89. Bioverativ Inc Corporation Information
Table 90. Bioverativ Inc Description and Business Overview
Table 91. Bioverativ Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 92. Bioverativ Inc Product
Table 93. Bioverativ Inc Recent Development
Table 94. Catalyst Biosciences Inc Corporation Information
Table 95. Catalyst Biosciences Inc Description and Business Overview
Table 96. Catalyst Biosciences Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 97. Catalyst Biosciences Inc Product
Table 98. Catalyst Biosciences Inc Recent Development
Table 99. Chugai Pharmaceutical Co Ltd Corporation Information
Table 100. Chugai Pharmaceutical Co Ltd Description and Business Overview
Table 101. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 102. Chugai Pharmaceutical Co Ltd Product
Table 103. Chugai Pharmaceutical Co Ltd Recent Development
Table 104. CSL Ltd Corporation Information
Table 105. CSL Ltd Description and Business Overview
Table 106. CSL Ltd Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 107. CSL Ltd Product
Table 108. CSL Ltd Recent Development
Table 109. DBV Technologies SA Corporation Information
Table 110. DBV Technologies SA Description and Business Overview
Table 111. DBV Technologies SA Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. DBV Technologies SA Product
Table 113. DBV Technologies SA Recent Development
Table 114. Dimension Therapeutics Inc Corporation Information
Table 115. Dimension Therapeutics Inc Description and Business Overview
Table 116. Dimension Therapeutics Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Dimension Therapeutics Inc Product
Table 118. Dimension Therapeutics Inc Recent Development
Table 119. EpiVax Inc Corporation Information
Table 120. EpiVax Inc Description and Business Overview
Table 121. EpiVax Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 122. EpiVax Inc Product
Table 123. EpiVax Inc Recent Development
Table 124. Expression Therapeutics LLC Corporation Information
Table 125. Expression Therapeutics LLC Description and Business Overview
Table 126. Expression Therapeutics LLC Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 127. Expression Therapeutics LLC Product
Table 128. Expression Therapeutics LLC Recent Development
Table 129. Green Cross Corp Corporation Information
Table 130. Green Cross Corp Description and Business Overview
Table 131. Green Cross Corp Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 132. Green Cross Corp Product
Table 133. Green Cross Corp Recent Development
Table 134. Idogen AB Corporation Information
Table 135. Idogen AB Description and Business Overview
Table 136. Idogen AB Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 137. Idogen AB Product
Table 138. Idogen AB Recent Development
Table 139. Immusoft Corp Corporation Information
Table 140. Immusoft Corp Description and Business Overview
Table 141. Immusoft Corp Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 142. Immusoft Corp Product
Table 143. Immusoft Corp Recent Development
Table 144. LFB SA Corporation Information
Table 145. LFB SA Description and Business Overview
Table 146. LFB SA Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 147. LFB SA Product
Table 148. LFB SA Recent Development
Table 149. mAbxience SA Corporation Information
Table 150. mAbxience SA Description and Business Overview
Table 151. mAbxience SA Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 152. mAbxience SA Product
Table 153. mAbxience SA Recent Development
Table 154. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 155. Key Challenges
Table 156. Market Risks
Table 157. Main Points Interviewed from Key Hemophilia A Drug Players
Table 158. Hemophilia A Drug Customers List
Table 159. Hemophilia A Drug Distributors List
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Hemophilia A Drug Product Picture
Figure 2. Global Hemophilia A Drug Sales Market Share by Type in 2020 & 2026
Figure 3. ATXF-8117 Product Picture
Figure 4. BAY-1093884 Product Picture
Figure 5. BIVV-001 Product Picture
Figure 6. BS-027125 Product Picture
Figure 7. Concizumab Product Picture
Figure 8. CSL-689 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Hemophilia A Drug Sales Market Share by Application in 2020 & 2026
Figure 11. Clinic
Figure 12. Hospital
Figure 13. ASCs
Figure 14. Hemophilia A Drug Report Years Considered
Figure 15. Global Hemophilia A Drug Market Size 2015-2026 (US$ Million)
Figure 16. Global Hemophilia A Drug Sales 2015-2026 (K Pcs)
Figure 17. Global Hemophilia A Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Hemophilia A Drug Sales Market Share by Region (2015-2020)
Figure 19. Global Hemophilia A Drug Sales Market Share by Region in 2019
Figure 20. Global Hemophilia A Drug Revenue Market Share by Region (2015-2020)
Figure 21. Global Hemophilia A Drug Revenue Market Share by Region in 2019
Figure 22. Global Hemophilia A Drug Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Hemophilia A Drug Revenue in 2019
Figure 24. Hemophilia A Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Hemophilia A Drug Sales Market Share by Type (2015-2020)
Figure 26. Global Hemophilia A Drug Sales Market Share by Type in 2019
Figure 27. Global Hemophilia A Drug Revenue Market Share by Type (2015-2020)
Figure 28. Global Hemophilia A Drug Revenue Market Share by Type in 2019
Figure 29. Global Hemophilia A Drug Market Share by Price Range (2015-2020)
Figure 30. Global Hemophilia A Drug Sales Market Share by Application (2015-2020)
Figure 31. Global Hemophilia A Drug Sales Market Share by Application in 2019
Figure 32. Global Hemophilia A Drug Revenue Market Share by Application (2015-2020)
Figure 33. Global Hemophilia A Drug Revenue Market Share by Application in 2019
Figure 34. Japan Hemophilia A Drug Sales Growth Rate 2015-2026 (K Pcs)
Figure 35. Japan Hemophilia A Drug Revenue Growth Rate 2015-2026 (US$ Million)
Figure 36. Japan Hemophilia A Drug Market Share in Global Market 2015-2026
Figure 37. Japan 5 and 10 Largest Hemophilia A Drug Players Market Share by Revenue in Hemophilia A Drug in 2019
Figure 38. Japan Hemophilia A Drug Revenue Share by Type (2015-2020)
Figure 39. Japan Hemophilia A Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 40. Japan Hemophilia A Drug Revenue Share by Application (2015-2020)
Figure 41. Japan Hemophilia A Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 42. North America Hemophilia A Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. North America Hemophilia A Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. North America Hemophilia A Drug Sales Market Share by Country in 2019
Figure 45. North America Hemophilia A Drug Revenue Market Share by Country in 2019
Figure 46. U.S. Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. U.S. Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Canada Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Canada Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Europe Hemophilia A Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 51. Europe Hemophilia A Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 52. Europe Hemophilia A Drug Sales Market Share by Country in 2019
Figure 53. Europe Hemophilia A Drug Revenue Market Share by Country in 2019
Figure 54. Germany Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Germany Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. France Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. France Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. U.K. Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. U.K. Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Italy Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. Italy Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Russia Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. Russia Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Asia Pacific Hemophilia A Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 65. Asia Pacific Hemophilia A Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 66. Asia Pacific Hemophilia A Drug Sales Market Share by Region in 2019
Figure 67. Asia Pacific Hemophilia A Drug Revenue Market Share by Region in 2019
Figure 68. China Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. China Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Japan Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Japan Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. South Korea Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. South Korea Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. India Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. India Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Australia Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Australia Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Taiwan Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Taiwan Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Indonesia Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Indonesia Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Thailand Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Thailand Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Malaysia Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Malaysia Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Philippines Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 87. Philippines Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Vietnam Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 89. Vietnam Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Latin America Hemophilia A Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 91. Latin America Hemophilia A Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 92. Latin America Hemophilia A Drug Sales Market Share by Country in 2019
Figure 93. Latin America Hemophilia A Drug Revenue Market Share by Country in 2019
Figure 94. Mexico Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Mexico Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Brazil Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Brazil Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Argentina Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 99. Argentina Hemophilia A Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Middle East and Africa Hemophilia A Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 101. Middle East and Africa Hemophilia A Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Hemophilia A Drug Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Hemophilia A Drug Revenue Market Share by Country in 2019
Figure 104. Turkey Hemophilia A Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure
  • Global Fibrinogen Concentrate Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The Fibrinogen Concentrate market covers Human Fibrinogen Concentrate, Other, etc. The typical players include CSL Behring, LFB, Shanghai RAAS, Boya, Hualan Biological Engineering, etc. The global Fibrinogen Concentrate market was valued at US$ 796 million in 2023 and is anticipated to reach US$ 2207.6 million by 2030, witnessing a CAGR of 15.5% during The forecast period 2024-2030. The major producers in The industry are CSL Behring, LFB Group and Shanghai RAAS B......
  • Global Fibrinogen Concentrate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 91
    According to our LPI (LP Information) latest study, the global Fibrinogen Concentrate market size was valued at US$ 778.7 million in 2023. With growing demand in downstream market, the Fibrinogen Concentrate is forecast to a readjusted size of US$ 2211.3 million by 2030 with a CAGR of 16.1% during review period. The research report highlights the growth potential of the global Fibrinogen Concentrate market. Fibrinogen Concentrate are expected to show stable growth in the future market. H......
  • Global Low Molecular Weight Heparin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 124
    Market Overview of Global Low Molecular Weight Heparin market: According to our latest research, the global Low Molecular Weight Heparin market looks promising in the next 5 years. As of 2022, the global Low Molecular Weight Heparin market was estimated at USD 359.23 million, and it's anticipated to reach USD 601.59 million in 2028, with a CAGR of 8.97% during the forecast years. Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. They are used in the......
  • Global Anticoagulants Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 106
    According to our LPI (LP Information) latest study, the global Anticoagulants market size was valued at US$ 25390 million in 2023. With growing demand in downstream market, the Anticoagulants is forecast to a readjusted size of US$ 35420 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Anticoagulants market. Anticoagulants are expected to show stable growth in the future market. However, product differentiation, r......
  • Global Injectable Anticoagulants Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Injectable Anticoagulants market size was valued at US$ 5959.5 million in 2023. With growing demand in downstream market, the Injectable Anticoagulants is forecast to a readjusted size of US$ 6929.9 million by 2030 with a CAGR of 2.2% during review period. The research report highlights the growth potential of the global Injectable Anticoagulants market. Injectable Anticoagulants are expected to show stable growth in the futu......
  • Global Low Molecular Weight Heparin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Low Molecular Weight Heparin market size was valued at US$ 331.2 million in 2023. With growing demand in downstream market, the Low Molecular Weight Heparin is forecast to a readjusted size of US$ 485.1 million by 2030 with a CAGR of 5.6% during review period. The research report highlights the growth potential of the global Low Molecular Weight Heparin market. Low Molecular Weight Heparin are expected to show stable growth i......
  • Global Heparin Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132
    According to our LPI (LP Information) latest study, the global Heparin Sodium market size was valued at US$ 3301.4 million in 2023. With growing demand in downstream market, the Heparin Sodium is forecast to a readjusted size of US$ 5093.5 million by 2030 with a CAGR of 6.4% during review period. The research report highlights the growth potential of the global Heparin Sodium market. Heparin Sodium are expected to show stable growth in the future market. However, product differentiation,......
  • Global Intravenous Immunoglobulin (IVIg) Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Intravenous Immunoglobulin (IVIg) market size was valued at US$ 10090 million in 2023. With growing demand in downstream market, the Intravenous Immunoglobulin (IVIg) is forecast to a readjusted size of US$ 15290 million by 2030 with a CAGR of 6.1% during review period. The research report highlights the growth potential of the global Intravenous Immunoglobulin (IVIg) market. Intravenous Immunoglobulin (IVIg) are expected to ......
  • Global Heparin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 128
    According to our LPI (LP Information) latest study, the global Heparin market size was valued at US$ 2286.2 million in 2023. With growing demand in downstream market, the Heparin is forecast to a readjusted size of US$ 3831.5 million by 2030 with a CAGR of 7.7% during review period. The research report highlights the growth potential of the global Heparin market. Heparin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs